Premium
THE CRITERIA OF INTERIM THERAPY CHANGE FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: INTERIM ΔSPD LESS THAN 80% VS. 50%
Author(s) -
Xu W.,
Wei Y.,
Ding C.,
Liang J.,
Wang L. Li,
Zhu H.,
Fan L.,
Li J.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.91_2631
Subject(s) - interim , medicine , statistical significance , interim analysis , diffuse large b cell lymphoma , nuclear medicine , clinical trial , lymphoma , archaeology , history